Association between Cytokines and Functional, Hemodynamic Parameters, and Clinical Outcomes in Pulmonary Arterial Hypertension

August 17, 2018
Cardiac, Cytokines / Chemokines, Inflammation
Aditya A. Joshi, Ryan Davey, Youlan Rao, Kai Shen, Raymond L. Benza, Amresh Raina

Read Full Article »

Pulmonary arterial hypertension (PAH) is a result of changes in the distal pulmonary vasculature that can lead to progressive debilitating symptoms and often result in death. While smooth muscle cell proliferation, endothelial dysfunction, and vascular inflammation are all believed to play important roles in PAH, but recently, more attention has been focused on inflammation mechanisms. Emerging evidence suggests that there may be circulating factors that can serve as biomarkers to monitor disease progression and treatment response. This study used patients enrolled in two clinical trials that were treated with treprostinil (TRUST-1 and FREEDOM-C2). Plasma was collected at baseline and at 12 or 16 week follow up and analyzed using DiscoveryMAP at Myriad RBM.

Read More

Blood Based Biomarker Test to Predict Major Cardiac Events

May 9, 2017
Blog, Cardiac, Utilized Myriad RBM's Services

Cardiovascular BiomarkersPrevencio, Inc. has announced data published in The American Journal of Cardiology, on a new proteomic blood test that determines whether a person will have a heart attack, stroke, or other major adverse cardiac event (MACE) more accurately than the currently used clinical risk factors.  A total of 927 patient samples were analyzed from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study undergoing coronary angiography.

Read More

Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia

November 19, 2015
Cardiac, Diabetes, Utilized Myriad RBM's Services

An international team of researchers used Myriad RBM’s Multi-Analyte Profile (MAP) technology to identify a pattern of cardiometabolic biomarkers that appears to predict cardiovascular outcomes in patients with dysglycemia. This data, the latest publication stemming from the landmark Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, holds great promise for prognosis and treatment of patients suffering from diseases caused by abnormalities in blood glucose levels.

Read Article »

ENRAGE: A Novel Inflammatory Marker for Incident Coronary Heart Disease

October 31, 2014
Cardiac, Inflammation, Utilized Myriad RBM's Services
This recent paper in the Arteriosclerosis, Thrombosis and Vascular Biology Journal of the American Heart Association describes an interesting prospective study of 839 coronary heart disease (CHD)-free individuals who were followed for about 10 years with blood based biomarker testing. As the mean age at the beginning of the study was 73 years, 99 individuals developed CHD over the 10 year period. Multiplexed immunoassays for 51 inflammatory biomarkers indicated that ENRAGE (extracellular newly identified receptor for advanced glycation end-products binding protein) was most strongly associated with risk for developing CHD. This association was not effected by diabetes, kidney disease or anti-hypertensive medication. https://atvb.ahajournals.org/content/early/2014/10/23/ATVBAHA.114.304306

New Biomarker Offers Hope for Early Detection of Cardiac Injury

February 27, 2014
Blog, Cardiac
Myocardial infarctions and acute coronary syndrome affect nearly 1 million Americans every year. These events result in damage to the heart tissue and lead to hospitalization with high levels of morbidity and mortality. Cardiac troponin is a biomarker that is elevated in plasma following these events but it lacks the sensitivity to detect early stage disease. New research has identified a more sensitive biomarker, cardiac myosin binding protein-C, that increases in blood concentration rapidly after a cardiac event and therefore may serve as a better clinical marker of cardiac damage. https://ajpheart.physiology.org/content/306/4/H547

Blood Protein May Contribute to Early Development of Atherosclerosis

May 23, 2013
Blog, Cardiac
A study conducted by Dr. Eric Thorin of the Montreal Heart Institute, suggests blood levels of angiopoietin-like protein 2 (angptl2) may represent an early biomarker for atherosclerosis. Researchers discovered levels of angptl2 are six times higher in mice with coronary heart disease than in healthy mice. Their study also revealed angptl2 levels increase with age in healthy subjects but increases prematurely in those subjects with high cholesterol and pre-atherosclerotic lesions. More research is needed, however if confirmed, these results represent a major advancement in the prevention and diagnosis of atherosclerosis.
1 2